Abstract

Objectives The aim of the present study is to evaluate the role of immunoglobulins (IgA, IgG, and IgM) and circulating immune complexes (CIC) as tumor marker in oral cancer and precancer patients. Materials and Methods The present study was performed on 45 individuals subdivided into three groups, that is, oral precancer, oral cancer and healthy individuals, and levels of immunoglobulins, and CIC was estimated by turbidometry and ELISA method. Results In the present study, the mean serum IgA levels in oral precancer were 161.00 ( ± 118.02) mg/dL, oral cancers were 270.67 ( ± 171.44) mg/dL, and controls were 133.73 ( ± 101.31) mg/dL. Mean serum levels of IgG in oral precancer were 1,430.87 ( ± 316) mg/dL, oral cancers were 1,234.27 ( ± 365.42) mg/dL, and controls were 593.87 ( ± 323.06) mg/dL. Conclusion We found that the levels of serum IgG and IgA were elevated consistently in precancer and cancer group, and Serum IgM levels were increased only in precancer. Also, significant increase in serum CIC levels were seen in oral precancer and cancer group on comparison with control.

Highlights

  • Oral cancer is an insidious devastating malignancy and is one of the five leading cancers in India

  • The aim of the present study is to evaluate the role of immunoglobulins (IgA, IgG, and IgM) and circulating immune complexes (CIC) as tumor marker in oral cancer and precancer patients

  • Materials and Methods The present study was performed on 45 individuals subdivided into three groups, that is, oral precancer, oral cancer and healthy individuals, and levels of immunoglobulins, and CIC was estimated by turbidometry and ELISA method

Read more

Summary

Introduction

Oral cancer is an insidious devastating malignancy and is one of the five leading cancers in India. 90% of them are squamous cell carcinomas (SCC), arise from the mucosal lining.[1] Oral cancer is generally preceded by potentially malignant lesions and conditions for a varying length of time. Detection of these diseases with the discovery of immunological markers at a clinical, histological, and molecular level has significant reduction in mortality and implementation of multidisciplinary treatment programs, leading to improvement of survivorship and better quality of life.[2]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call